# Epidemiology of HIV/AIDS

The global pandemic of HIV/AIDS (human immunodeficiency virus infection and acquired immunodeficiency syndrome) began in 1981, and is an ongoing worldwide public health issue. According to the World Health Organization (WHO), by 2023, HIV/AIDS had killed approximately 40.4 million people, and approximately 39 million people were infected with HIV globally. Of these, 29.8 million people (75%) are receiving antiretroviral treatment. There were about 630,000 deaths from HIV/AIDS in 2022. The 2015 Global Burden of Disease Study estimated that the global incidence of HIV infection peaked in 1997 at 3.3 million per year. Global incidence fell rapidly from 1997 to 2005, to about 2.6 million per year. Incidence of HIV has continued to fall, decreasing by 23% from 2010 to 2020, with progress dominated by decreases in Eastern Africa and Southern Africa. As of 2023, there are about 1.3 million new infections of HIV per year globally.
HIV originated in nonhuman primates in Central Africa and jumped to humans several times in the late 19th or early 20th century. One reconstruction of its genetic history suggests that HIV-1 group M, the strain most responsible for the global epidemic, may have originated in Kinshasa, the capital of the Democratic Republic of the Congo, around 1920. AIDS was first recognized in 1981, and in 1983 HIV was discovered and identified as the cause of AIDS.
Throughout the world, HIV disproportionately affects certain key populations (sex workers and their clients, men who have sex with men, people who inject drugs, and transgender people) and their sexual partners. These groups account for 65% of global HIV infections, and 93% of new infections outside of sub-Saharan Africa. In Western Europe and North America, men who have sex with men account for almost two thirds of new HIV infections. In Sub-Saharan Africa, 63% of new infections are women, with young women (aged 15 to 24 years) twice as likely as men of the same age to be living with HIV.
According to the WHO, the prevalence of HIV in the Africa Region was estimated at 1.1 million people as of 2018. The African Region accounts for two thirds of the incidence of HIV around the world. Sub-Saharan Africa is the region most affected by HIV. As of 2020, more than two thirds of those living with HIV are living in Africa. HIV rates have been decreasing in the region: From 2010 to 2020, new infections in eastern and southern Africa fell by 38%. Still, South Africa has the largest population of people with HIV of any country in the world, at 8.45 million, 13.9% of the population as of 2022.
In Western Europe and North America, most people with HIV are able to access treatment and live long and healthy lives. As of 2020, 88% of people living with HIV in this region know their HIV status, and 67% have suppressed viral loads. In 2019, approximately 1.2 million people in the United States had HIV; 13% did not realize that they were infected. In Canada as of 2016, there were about 63,110 cases of HIV. In 2020, 106,890 people were living with HIV in the UK and 614 died (99 of these from COVID-19 comorbidity). In Australia, as of 2020, there were about 29,090 cases.

## Global HIV data

Since the first case of HIV/AIDS reported in 1981, this virus continues to be one of the most prevalent and deadliest pandemics worldwide. The Center for Disease Control mentions that the HIV disease continues to be a serious health issue for several parts of the world. Worldwide, there were about 1.7 million new cases of HIV reported in 2018. About 37.9 million people were living with HIV around the world in 2018, and 24.5 million of them were receiving medicines to treat HIV, called antiretroviral therapy (ART). In addition, roughly an estimated 770,000 people have died from AIDS-related illnesses in 2018.
Although AIDS is a global disease, the CDC reports that Sub-Saharan Africa has the highest prevalence of HIV and AIDS worldwide, and accounts for approximately 61% of all new HIV infections. Other regions significantly affected by HIV and AIDS include Asia and the Pacific, Latin America and the Caribbean, Eastern Europe, and Central Asia.
Worldwide there is a common stigma and discrimination surrounding HIV/AIDS. Respectively, infected patients are more subject to judgement, harassment, and acts of violence and come from marginalized areas where it is common to engage in illegal practices in exchange for money, drugs, or other exchangeable forms of currency.
AVERT, an international HIV and AIDS charity created in 1986, makes continuous efforts to prioritize, normalize, and provide the latest information and education programs on HIV and AIDS for individuals and areas most affected by this disease worldwide. AVERT suggested that discrimination and other human rights violations may occur in health care settings, barring people from accessing health services or enjoying quality health care.
Accessibility to tests have also played a significant role in the response and speed to which nations take action. Approximately 81% of people with HIV globally knew their HIV status in 2019. The remaining 19% (about 7.1 million people) still need access to HIV testing services. HIV testing is an essential gateway to HIV prevention, treatment, care and support services. It is crucial to have HIV tests available for individuals worldwide since it can help individuals detect the status of their disease from an early onset, seek help, and prevent further spread through the practice of suggestive safety precautions. Testing can be done for those between the ages of 13 and 64. The CDC recommends testing for HIV at least once for routine health care. HIV tests have a high accuracy and the tests come in the form of antibody tests, antigen/antibody tests, and NATS (nucleic acid test).
There were approximately 38 million people across the globe with HIV/AIDS in 2019. Of these, 36.2 million were adults and 1.8 million were children under 15 years old.
HIV/AIDS related deaths, HIV Incidence Rate, and HIV Prevalence Rate on a Global Scale :
| Year | Deaths due to HIV/AIDS globally | HIV Infection Incidence Rate globally | HIV Infection Prevalence Rate Globally |
| 1990 | 336 387 | 2 100 000 | 8 500 000 |
| 1995 | 939 400 | 3 200 000 | 18 600 000 |
| 2000 | 1 560 000 | 2 900 000 | 26 000 000 |
| 2005 | 1 830 000 | 2 500 000 | 28 500 000 |
| 2010 | 1 370 000 | 2 200 000 | 30 800 000 |
| 2015 | 1 030 000 | 1 900 000 | 34 400 000 |
| 2021 | 650 000 | 1 500 000 | 38 400 000 |

## Historical data for selected countries

HIV/AIDS in World from 2001 to 2014 – adult prevalence – data from CIA World Factbook
HIV in World in 2014 :
| Region/Country | 2014 | 2013 | 2012 | 2009 | 2007 | 2003 | 2001 |
| World | 0.79% | NA | 0.8% | 0.8% | 0.8% | NA | NA |
| Africa |
| North Africa |
| Sudan | 0.25% | 0.24% | NA | 1.1% | 1.4% | NA | 2.3% |
| Egypt | 0.02% | 0.02% | NA | <0.1% | NA | NA | <0.1% |
| Libya | NA | NA | 0.3% | NA | NA | NA | 0.3% |
| Tunisia | 0.04% | 0.05% | NA | <0.1% | <0.1% | <0.1% (2005) | NA |
| Algeria | 0.04% | 0.1% | NA | 0.1% | 0.1% | NA | 0.1% |
| Morocco | 0.14% | 0.16% | NA | 0.1% | 0.1% | NA | 0.1% |
| Mauritania | 0.92% | NA | 0.4% | 0.7% | 0.8% | 0.6% | NA |
| Western Africa |
| Senegal | 0.53% | 0.46% | NA | 0.9% | 1% | 0.8% | NA |
| The Gambia | 1.82% | 1.2% | NA | 2% | 0.9% | 1.2% | NA |
| Guinea Bissau | 3.69% | 3.74% | NA | 2.5% | 1.8% | 10% | NA |
| Guinea | 1.55% | 1.74% | NA | 1.3% | 1.6% | 3.2% | NA |
| Sierra Leone | 1.4% | 1.55% | NA | 1.6% | 1.7% | NA | 7% |
| Liberia | 1.17% | 1.09% | NA | 1.5% | 1.7% | 5.9% | NA |
| Cote d'Ivore | 3.46% | 2.67% | NA | 3.4% | 3.9% | 7% | NA |
| Ghana | 1.47% | 1.3% | NA | 1.8% | 1.9% | 3.1% | NA |
| Togo | 2.4% | 2.33% | NA | 3.2% | 3.3% | 4.1% | NA |
| Benin | 1.14% | 1.13% | NA | 1.2% | 1.2% | 1.9% | NA |
| Nigeria | 3.17% | 3.17% | NA | 3.6% | 3.1% | 5.4% | NA |
| Niger | 0.49% | 0.4% | NA | 0.8% | 0.8% | 1.2% | NA |
| Burkina Faso | 0.94% | NA | 1% | 1.2% | 1.6% | 4.2% | NA |
| Mali | 1.42% | 0.86% | NA | 1% | 1.5% | 1.9% | NA |
| Cape Verde | 1.09% | 0.47% | NA | NA | NA | NA | 0.04% |
| Central Africa |
| Chad | 2.53% | 2.48% | NA | 3.4% | 3.5% | 4.8% | NA |
| Cameroon | 4.77% | 4.27% | NA | 5.3% | 5.1% | 6.9% | NA |
| Central African Republic | 4.25% | 3.82% | NA | 4.7% | 6.3% | 13.5% | NA |
| São Tomé and Príncipe | 0.78% | 0.64% | NA | NA | NA | NA | NA |
| Equatorial Guinea | 6.16% | NA | 6.2% | 5% | 3.4% | NA | 3.4% |
| Gabon | 3.91% | 3.9% | NA | 5.2% | 5.9% | 8.1% | NA |
| Republic of the Congo | 2.75% | 2.49% | NA | 3.4% | 3.5% | 4.9% | NA |
| Democratic Republic of the Congo | 1.04% | 1.08% | NA | NA | NA | 4.2% | NA |
| Angola | 2.41% | 2.35% | NA | 2% | 2.1% | 3.9% | NA |
| Eastern Africa |
| Eritrea | 0.68% | 0.62% | NA | 0.8% | 1.3% | 2.7% | NA |
| Djibouti | 1.59% | 0.91% | NA | 2.5% | 3.1% | 2.9% | NA |
| Somalia | 0.55% | 0.53% | NA | 0.7% | 0.5% | NA | 1% |
| Ethiopia | 1.15% | 1.2% | NA | NA | 2.1% | 4.4% | NA |
| South Sudan | 2.71% | 2.24% | NA | 3.1% | NA | NA | NA |
| Kenya | 5.3% | 6.04% | NA | 6.3% | NA | 6.7% | NA |
| Uganda | 7.25% | 7.44% | NA | 6.5% | 5.4% | 4.1% | NA |
| Rwanda | 2.82% | 2.85% | NA | 2.9% | 2.8% | 5.1% | NA |
| Burundi | 1.11% | 1.03% | NA | 3.3% | 2% | 6% | NA |
| Tanzania | 5.34% | 4.95% | NA | 5.6% | 6.2% | 8.8% | NA |
| Malawi | 10.04% | 10.25% | NA | 11% | 11.9% | 14.2% | NA |
| Mozambik | 10.58% | 10.75% | NA | 11.5% | 12.5% | 12.2% | NA |
| Zambia | 12.37% | 12.5% | NA | 13.5% | 15.2% | 16.5% | NA |
| Zimbabwe | 16.74% | 14.99% | NA | 14.3% | 15.3% | NA | 24.6% |
| Madagascar | 0.29% | 0.4% | NA | 0.2% | 0.1% | 1.7% | NA |
| Comoros | NA | NA | 0.1% | 0.1% | <0.1% | NA | 0.12% |
| Mauritius | 0.92% | 1.1% | NA | 1% | 1.7% | NA | 0.1% |
| Southern Africa |
| Namibia | 15.97% | 14.3% | NA | 13.1% | 15.3% | 21.3% | NA |
| Botswana | 25.16% | 21.86% | NA | 24.8% | 23.9% | 37.3% | NA |
| Eswatini | 27.73% | 27.36% | NA | 25.9% | 26.1% | 38.8% | NA |
| Lesotho | 23.39% | 22.95% | NA | 23.6% | 23.2% | 28.9% | NA |
| South Africa | 18.92% | 19.05% | NA | 17.8% | 18.1% | 21.5% | NA |
| Asia |
| Western Asia |
| Georgia | 0.28% | 0.27% | NA | 0.1% | <0.1% | NA | <0.1% |
| Armenia | 0.22% | 0.19% | NA | 0.1% | 0.1% | 0.1% | NA |
| Azerbaijan | 0.14% | 0.16% | NA | 0.1% | <0.2%% | <0.1% | NA |
| Turkey | NA | NA | <0.1% | <0.1% | NA | NA | <0.1% |
| Iran | 0.14% | 0.14% | NA | 0.2% | 0.2% | 0.2% (2005) | NA |
| Iraq | NA | NA | <0.1% | NA | NA | NA | <0.1% |
| Syria | 0.01% | NA | <0.1% | NA | NA | NA | <0.1% |
| Jordan | NA | NA | <0.1% | NA | NA | NA | <0.1% |
| Lebanon | 0.06% | NA | 0.1% | 0.1% | 0.1% | NA | 0.1% |
| Israel | NA | NA | 0.2% | 0.2% | 0.1% | NA | 0.1% |
| Yemen | 0.05% | 0.04% | NA | NA | NA | NA | 0.1% |
| Oman | 0.16% | NA | 0.1% | 0.1% | NA | NA | 0.1% |
| United Arab Emirates | NA | NA | 0.2% | NA | NA | NA | 0.18% |
| Qatar | NA | NA | <0.1% | <0.1% | NA | NA | 0.09% |
| Bahrain | NA | NA | 0.2% | NA | NA | NA | 0.2% |
| Kuwait | NA | NA | 0.1% | NA | NA | NA | 0.12% |
| Central Asia |
| Kazakhstan | NA | NA | 0.1% | 0.1% | 0.1% | NA | 0.2% |
| Uzbekistan | 0.15% | 0.18% | NA | 0.1% | <0.1% | NA | <0.1% |
| Turkmenistan | NA | NA | <0.1% | NA | <0.1% | <0.1% (2004) | NA |
| Kyrgyzstan | 0.26% | 0.24% | NA | 0.3% | <0.1% | NA | <0.1% |
| Tajikistan | 0.35% | 0.31% | NA | 0.2% | <0.3% | NA | <0.1% |
| Afghanistan | 0.04% | NA | <0.1% | NA | NA | NA | <0.1% |
| Southern Asia |
| Pakistan | 0.09% | 0.07% | NA | 0.1% | 0.1% | NA | 0.1% |
| Nepal | 0.2% | 0.23% | NA | 0.4% | 0.5% | NA | 0.5% |
| Bhutan | NA | 0.13% | NA | 0.2% | <0.1% | NA | <0.1% |
| India | NA | 0.26% | NA | 0.3% | 0.3% | NA | 0.9% |
| Bangladesh | 0.01% | 0.01% | NA | <0.1% | NA | NA | <0.1% |
| Sri Lanka | 0.03% | 0.02% | NA | <0.1% | NA | NA | <0.1% |
| Maldives | NA | 0.01% | NA | <0.1% | NA | NA | 0.1% |
| Southeastern Asia |
| Myanmar (Burma) | 0.69% | 0.61% | NA | 0.6% | 0.7% | 1.2% | NA |
| Thailand | 1.13% | 1.09% | NA | 1.3% | 1.4% | 1.5% | NA |
| Laos | 0.26% | 0.15% | NA | 0.2% | 0.2% | 0.1% | NA |
| Cambodia | 0.64% | 0.74% | NA | 0.5% | 0.8% | 2.6% | NA |
| Vietnam | 0.47% | 0.4% | NA | 0.4% | 0.5% | 0.4% | NA |
| Malaysia | 0.45% | 0.44% | NA | 0.5% | 0.5% | 0.4% | NA |
| Singapore | NA | NA | 0.1% | 0.1% | 0.2% | 0.2% | NA |
| Brunei | NA | NA | <0.1% | NA | NA | <0.1% | NA |
| Philippines | NA | NA | 0.1% | <0.1% | NA | <0.1% | NA |
| Indonesia | 0.47% | 0.46% | NA | 0.2% | 0.2% | 0.1% | NA |
| Eastern Asia |
| Mongolia | NA | 0.04% | NA | <0.1% | <0.1% | <0.1% | NA |
| Japan | NA | NA | <0.1% | <0.1% | NA | <0.1% | NA |
| South Korea | NA | NA | <0.1% | <0.1% | <0.1% | <0.1% | NA |
| China | NA | NA | 0.1% | 0.1% | 0.1% | 0.1% | NA |
| Hong Kong | NA | NA | 0.1% | NA | NA | 0.1% | NA |
| Australia and Oceania |
| Australia | NA | 0.17% | NA | 0.1% | 0.2% | 0.1% | NA |
| New Zealand | NA | NA | 0.1% | 0.1% | 0.1% | 0.1% | NA |
| Papua New Guinea | 0.72% | 0.65% | NA | 0.9% | 1.5% | 0.6% | NA |
| Fiji | 0.13% | 0.1% | NA | 0.1% | 0.1% | 0.1% | NA |
| Americas |
| North America |
| Canada | NA | NA | 0.3% | 0.3% | 0.3% | 0.3% | NA |
| Mexico | 0.23% | 0.23% | NA | 0.3% | 0.3% | 0.3% | NA |
| USA | NA | NA | 0.6% | 0.6% | 0.6% | 0.6% | NA |
| Bermuda | | NA | 0.3% | NA | NA | 0.3% (2005) | NA |
| Central America |
| Belize | 1.18% | 1.49% | NA | 2.3% | 2.1% | 2.4% | NA |
| Guatemala | 0.54% | 0.59% | NA | 0.8% | 0.8% | 1.1% | NA |
| El Salvador | 0.53% | 0.53% | NA | 0.8% | 0.8% | 0.7% | NA |
| Honduras | 0.42% | 0.47% | NA | 0.8% | 0.7% | 1.8% | NA |
| Nicaragua | 0.27% | 0.19% | NA | 0.2% | 0.2% | 0.2% | NA |
| Costa Rica | 0.26% | 0.23% | NA | 0.3% | 0.4% | 0.6% | NA |
| Panama | 0.65% | 0.65% | NA | 0.9% | 1% | 0.9% | NA |
| Caribbean |
| The Bahamas | NA | 3.22% | NA | 3.1% | 3% | 3% | NA |
| Cuba | 0.25% | 0.23% | NA | 0.1% | <0.1% | <0.1% | NA |
| Jamaica | 1.62% | 1.75% | NA | 1.7% | 1.6% | 1.2% | NA |
| Haiti | 1.93% | 1.97% | NA | 1.9% | 2.2% | 5.6% | NA |
| Dominican Republic | 1.04% | 0.7% | NA | 0.9% | 1.1% | 1.7% | NA |
| Barbados | NA | 0.88% | NA | 1.4% | 1.2% | 1.5% | NA |
| Trinidad and Tobago | NA | 1.65% | NA | 1.5% | 1.5% | 3.2% | NA |
| South America |
| Suriname | 1.02% | 0.88% | NA | 1% | 2.4% | | 1.7% |
| Guyana | 1.81% | 1.38% | NA | 1.2% | 2.5% | 2.5% | NA |
| Venezuela | 0.55% | 0.56% | NA | NA | NA | NA | 0.7% |
| Colombia | 0.4% | 0.45% | NA | 0.5% | 0.6% | 0.7% | NA |
| Ecuador | 0.34% | 0.41% | NA | 0.4% | 0.3% | 0.3% | NA |
| Peru | 0.36% | 0.35% | NA | 0.4% | 0.5% | 0.5% | NA |
| Bolivia | 0.29% | 0.25% | NA | 0.2% | 0.2% | 0.1% | NA |
| Chile | 0.29% | 0.33% | NA | 0.4% | 0.3% | 0.3% | NA |
| Paraguay | 0.41% | 0.4% | NA | 0.3% | 0.6% | 0.5% | NA |
| Uruguay | 0.7% | 0.71% | NA | 0.5% | 0.6% | NA | 0.3% |
| Argentina | 0.47% | NA | 0.4% | 0.5% | 0.5% | NA | 0.7% |
| Brazil | NA | 0.55% | NA | NA | 0.6% | 0.7% | NA |
| Europe |
| Russia | NA | NA | 1% | 1% | 1% | NA | 1.1% |
| Ukraine | NA | 0.83% | NA | 1.1% | 1.6% | 1.4% | NA |
| Estonia | NA | 1.3% | NA | 1.2% | 1.3% | NA | 1.1% |
| Latvia | NA | NA | 0.7% | 0.7% | 0.8% | NA | 0.6% |
| Lithuania | NA | NA | NA | 0.1% | 0.1% | NA | 0.1% |
| Belarus | 0.52% | 0.49% | NA | 0.3% | 0.2% | NA | 0.3% |
| Poland | 0.07% | NA | NA | 0.1% | 0.1% | NA | 0.1% |
| Moldova | 0.63% | 0.61% | NA | 0.4% | 0.4% | NA | 0.2% |
| Romania | NA | 0.11% | NA | 0.1% | <0.1% | NA | <0.1% |
| Bulgaria | NA | NA | 0.1% | 0.1% | NA | NA | <0.1% |
| Czech Republic | NA | 0.05% | NA | <0.1% | NA | NA | <0.1% |
| Slovakia | 0.02% | NA | <0.1% | <0.1% | NA | NA | <0.1% |
| Slovenia | 0.08% | NA | <0.1% | <0.1% | <0.1% | NA | <0.1% |
| Hungary | NA | NA | <0.1% | <0.1% | 0.1% | NA | 0.1% |
| Croatia | NA | NA | <0.1% | <0.1% | <0.1% | NA | <0.1% |
| Bosnia and Herzegovina | NA | NA | <0.1% | NA | <0.1% | NA | <0.1% |
| Serbia | NA | 0.05% | NA | 0.1% | NA | NA | NA |
| Albania | NA | 0.04% | NA | NA | NA | NA | NA |
| Macedonia | NA | 0.01% | NA | NA | <0.1% | NA | <0.1% |
| Greece | NA | NA | 0.1% | 0.1% | 0.2% | NA | 0.2% |
| Cyprus | NA | 0.06% | NA | NA | NA | 0.1% | NA |
| Malta | NA | NA | 0.1% | 0.1% | 0.1% | NA | 0.2% |
| Italy | NA | 0.28% | NA | 0.3% | 0.4% | NA | 0.5% |
| Portugal | NA | NA | 0.6% | 0.6% | 0.5% | NA | 0.4% |
| Spain | NA | 0.42% | NA | 0.4% | 0.5% | NA | 0.7% |
| France | NA | NA | 0.4% | 0.4% | 0.4% | 0.4% | NA |
| Netherlands | NA | NA | 0.2% | 0.2% | 0.2% | NA | 0.2% |
| Belgium | NA | NA | 0.2% | 0.2% | 0.2% | 0.2% | NA |
| Luxembourg | NA | NA | 0.3% | 0.3% | 0.2% | NA | 0.2% |
| Switzerland | NA | 0.35% | 0.2% | 0.2% | 0.2% | 0.2% | NA |
| Austria | NA | NA | 0.3% | 0.3% | 0.2% | 0.3% | NA |
| Germany | NA | 0.15% | NA | 0.1% | 0.1% | NA | 0.1% |
| Denmark | 0.16% | 0.16% | NA | 0.2% | 0.2% | 0.2% | NA |
| Finland | NA | NA | 0.1% | 0.1% | <0.1% | <0.01% | NA |
| Sweden | NA | NA | 0.1% | 0.1% | 0.1% | NA | 0.1% |
| Norway | NA | NA | 0.1% | 0.1% | 0.1% | NA | 0.1% |
| Iceland | NA | NA | 0.3% | 0.3% | 0.2% | NA | 0.2% |
| Ireland | NA | NA | 0.2% | 0.2% | 0.2% | NA | 0.1% |
| United Kingdom | NA | 0.33% | NA | 0.2% | 0.2% | NA | 0.2% |

## By region

The global epidemic is not homogeneous within regions, with some countries more affected than others. Even at the country level, there are wide variations in infection levels between different areas and different population groups. New HIV infections are falling globally on average (a decrease of 23% from 2010 to 2020), but continue to rise in many parts of the world. Sub-Saharan Africa is by far the worst-affected region, and targeted interventions in the region have decreased the spread of HIV. New infections fell in eastern and southern Africa by 38% from 2010 to 2020, but HIV in western and central Africa has not received the same attention, and as a result has made less progress. HIV rates have declined slightly in Asia and the Pacific, with HIV decreasing in Mainland Southeast Asia, but increasing in the Philippines and Pakistan. From 2010 to 2020, HIV infections increased by 21% in Latin America, 22% in the Middle East and North Africa, and 72% in Eastern Europe and central Asia.
Most people in North America and western and central Europe with HIV are able to access treatment and live long and healthy lives. Annual AIDS deaths have been continually declining since 2005 as antiretroviral therapy has become more widely available.
2020/2021 HIV Regional data :
| Region | People living with HIV 2020 (adults and children) | People living with HIV 2021 (adults and children) | Adult prevalence 2021 (%) Ages 15–49 | New infections 2020 (per year) | Adult HIV Incidence Rate 2021 (per 1000 people) | AIDS-related deaths in 2020 | AIDS-related deaths in 2021 | People accessing treatment | People receiving Antiretroviral Treatment (ART) 2021 | Prevalence of those receiving ART 2021 |
| Eastern and southern Africa | 20.6 million | 20.6 million | 6.2 | 670,000 | 2.39 | 310,000 | 280 000 | 16 million | 16 200 000 | 78 |
| Asia and the Pacific | 5.7 million | 6 million | 0.2 | 280,000 | 0.10 | 140,000 | 140 000 | 3.6 million | 4 000 000 | 66 |
| Western and central Africa | 4.7 million | 5 million | 1.3 | 200,000 | 0.46 | 150,000 | 140 000 | 3.5 million | 3 900 000 | 78 |
| Latin America | 2.1 million | 2.2 million | 0.5 | 110,000 | 0.30 | 32,000 | 29 000 | 1.4 million | 1 500 000 | 69 |
| The Caribbean | 330 000 | 330 000 | 1.2 | 13,000 | 0.57 | 6,000 | 5700 | 220,000 | 230 000 | 70 |
| Middle East and north Africa | 230 000 | 180 000 | <0.1 | 16,000 | 0.06 | 7,900 | 5100 | 93,000 | 88 000 | 50 |
| Eastern Europe and central Asia | 1.6 million | 1.8 million | 1.1 | 140,000 | 1.00 | 35,000 | 44 000 | 870,000 | 930 000 | 51 |
| Western and central Europe and North America | 2.2 million | 2.3 million | 0.3 | 67,000 | 0.12 | 13,000 | 13 000 | 1.9 million | 1 900 000 | 85 |
| Global totals | 37.6 million | 38.4 million | 0.7 | 1.5 million | 0.31 | 690,000 | 650 000 | 27.4 million | 28 700 000 | 75 |
Regional data 2010 :
| World region | Estimated prevalence of HIV infection (millions of adults and children) | Estimated adult and child deaths during 2010 | Adult prevalence (%) |
| Worldwide | 31.6–35.2 | 1.6–1.9 million | 0.8% |
| Sub-Saharan Africa | 21.6–24.1 | 1.2 million | 5.0% |
| South and South-East Asia | 3.6–4.5 | 250,000 | 0.3% |
| Eastern Europe and Central Asia | 1.3–1.7 | 90,000 | 0.9% |
| Latin America | 1.2–1.7 | 67,000 | 0.4% |
| North America | 1–1.9 | 20,000 | 0.6% |
| East Asia | 0.58–1.1 | 56,000 | 0.1% |
| Western and Central Europe | .77–.93 | 9,900 | 0.2% |

### Sub-Saharan Africa

Sub-Saharan Africa remains the hardest-hit region. HIV infection is becoming endemic in sub-Saharan Africa, which is home to just over 12% of the world's population but two-thirds of all people infected with HIV. As of 2022, it is estimated that the adult HIV prevalence rate is 6.2%, a 1.2% increase from data reported in the 2011 UNAIDS World Aids Day Report. However, the actual prevalence varies between regions. The UNAIDS 2021 data estimates that about 58% of the HIV 4000 incidences per day are in Sub-Saharan Africa. Presently, Southern Africa is the hardest hit region, with adult prevalence rates exceeding 20% in most countries in the region, and 30% in Eswatini and Botswana. Analysis of prevalence across sub-Saharan Africa between 2000 and 2017 found high variation in prevalence at a subnational level, with some countries demonstrating a more than five-fold difference in prevalence between different districts. Although Eastern and Southern Africa have a heavier burden of disease they have also shown much resilience in their response to HIV.
Across Sub-Saharan Africa, more women are infected with HIV than men, with 13 women infected for every 10 infected men. This gender gap continues to grow. Throughout the region, women are being infected with HIV at earlier ages than men. The differences in infection levels between women and men are most pronounced among young people (aged 15–24 years). In this age group, there are 36 women infected with HIV for every 10 men. The widespread prevalence of sexually transmitted diseases, the promiscuous culture, the practice of scarification, unsafe blood transfusions, and the poor state of hygiene and nutrition in some areas may all be facilitating factors in the transmission of HIV-1 (Bentwich et al., 1995).
It is important to work towards eliminating Mother-to-child transmission of HIV-1 in developing nations. Due to a lack of testing, a shortage in antenatal therapies and through the feeding of contaminated breast milk, 590,000 infants born in developing countries are infected with HIV-1 per year. In 2000, the World Health Organization estimated that 25% of the units of blood transfused in Africa were not tested for HIV, and that 10% of HIV infections in Africa were transmitted via blood.
Poor economic conditions (leading to the use of dirty needles in healthcare clinics) and lack of sex education contribute to high rates of infection. In some African countries, 25% or more of the working adult population is HIV-positive. Poor economic conditions caused by slow onset-emergencies, such as drought, or rapid onset natural disasters and conflict can result in young women and girls being forced into using sex as a survival strategy. Worse still, research indicates that as emergencies, such as drought, take their toll and the number of potential 'clients' decreases, women are forced by clients to accept greater risks, such as not using contraceptives.
AIDS-denialist policies have impeded the creation of effective programs for distribution of antiretroviral drugs. Denialist policies by former South African President Thabo Mbeki's administration led to several hundred thousand unnecessary deaths. UNAIDS estimates that in 2005 there were 5.5 million people in South Africa infected with HIV — 12.4% of the population. According to a graph done by UNAIDS, there were 4 200 000 people living with HIV in South Africa in 2005. This was an increase of 400 000 people since 2003. As of 2018, the prevalence of HIV in Eastern and Southern Africa combined was 1.8 million. This number only represents children and adolescents (Ages 0–19). As for those ages 15–24 in this region of Africa, the incidence rate (2018) was 290 000. About 203 000 of those infected were females. The statistical release form the Republic of South Africa in 2020 states that the prevalence rate of HIV infections among adults ages 15–49 was 18.7% but the overall population in South Africa has a prevalence rate of 13%. As of 2021, UNAIDS data from the eastern and southern countries in Africa showed the HIV prevalence rate to be 6.2% in adults ages 15–49.
Females in Sub-Saharan Africa continue to be adversely affected by HIV with data that reveals women 15–24 years of age are two times as likely to contract HIV compared to their male counterparts. However, it has been noted, that empowering women when it comes to education has an effect on lowering their risk of becoming infected with HIV. Data from Sub-Saharan Africa also shows that women are more likely to get tested for HIV, therefore a higher percentage of women compared to men are aware that they have HIV. There are also a higher percentage of women who are receiving treatment and women are more likely to continue with treatment once started.
Although HIV infection rates are much lower in Nigeria than in other African countries, the size of Nigeria's population meant that by the end of 2003, there were an estimated 3.6 million people infected. On the other hand, Uganda, Zambia, Senegal, and most recently Botswana have begun intervention and educational measures to slow the spread of HIV, and Uganda has succeeded in actually reducing its HIV infection rate.
During COVID-19, some countries in South and East Africa were able to set up treatment sites that provided 1.8 million individuals with a larger supply of antiretroviral (ART) medication that could sustain them for longer than the typical 3 months. In the quarterly report following lockdown, they saw a 10% decrease in the number of individuals that experienced treatment interruptions from the quarter before lockdown. South Africa also saw that those infected with HIV had a great risk of complications if they contracted the COVID-19 virus, and more so if they were not receiving ART. The other issue seen before the COVID-19 pandemic arrived was the lack of health care workers. In a bar graph created by the World Health Organization (WHO) comparing regions and globally, Sub-Saharan Africa had the least number of health professionals per 10 000 people.

### Middle East and North Africa

HIV/AIDS prevalence among the adult population (15-49) in the Middle East and North Africa (MENA) is estimated less than 0.1 between 1990 and 2018. This is the lowest prevalence rate compared to other regions in the world.
In the MENA, roughly 230,000 people are living with HIV as of 2020, a slight decrease from 240,000 in 2018 where Iran accounted for approximately one-quarter (61,000) of the population with HIV followed by Sudan (59,000). As well as, Sudan (5,200), Iran (4,400) and Egypt (3,600) took up more than 60% of the number of new infections themselves in the MENA (20,000). Roughly two-thirds of AIDS-related deaths in this region happened in these countries for the year 2018.
Although the prevalence is low, concerns remain in this region. First, unlike the global downward trend in new HIV infections and AIDS-related deaths, the numbers have continuously increased in the MENA. Second, compared to the global rate of antiretroviral therapy (62%), the MENA region's rate is far below in 2020 (43%). The low participation of antiretroviral therapy (ART) increases not only the number of AIDS-related deaths but the risk of mother-to-baby HIV infections, in which the MENA (24.7%) shows relatively high rates compared to other regions, for example, southern Africa (10%), Asia and the Pacific (17%). It is estimated that only one in five individuals in need of ART will receive it, and even less than 10% in women and children.
Key population at high risk in this region is identified as injection drug users, female sex workers and men who have sex with men.

### South and South-East Asia

The geographical size and human diversity of South and South-East Asia have resulted in HIV epidemics differing across the region.
In South and Southeast Asia, the HIV epidemic remains largely concentrated in injecting drug users (or people who inject drugs, PWID), men who have sex with men (MSM), sex workers, and clients of sex workers and their immediate sexual partners. In the Philippines, in particular, sexual contact between males comprise the majority of new infections. An HIV surveillance study conducted by Dr. Louie Mar Gangcuangco and colleagues from the University of the Philippines-Philippine General Hospital showed that out of 406 MSM tested for HIV in Metro Manila, HIV prevalence was 11.8% (95% confidence interval: 8.7- 15.0).
Migrants, in particular, are vulnerable and 67% of those infected in Bangladesh and 41% in Nepal are migrants returning from India. This is in part due to human trafficking and exploitation, but also because even those migrants who willingly go to India in search of work are often afraid to access state health services due to concerns over their immigration status.
Overall, integration of treatment and prevention programs has greatly increased in recent times since 2010. Condom programs have been most prevalent in the region and testing has increased disease HIV status awareness from 26 to 89% in the general region. Antiretroviral therapy has been successful in Thailand in eliminating mother-to-child transmission of both HIV and syphilis. Some countries have implemented needle and syringe exchange programs to combat PWID-related infections. In 2015, Bangladesh, India, Myanmar, Indonesia, Nepal, and Thailand all achieved the 200 needles distributed per PWID standard set by the World Health Organization (WHO) five years before the 2020 goal. Throughout the region, countries have seen a decrease in AIDS-related deaths and new HIV infections from 2010 to 2015, with the exception of Indonesia.

### East Asia

The national HIV prevalence levels in East Asia is 0.1% in the adult (15–49) group. However, due to the large populations of many East Asian nations, this low national HIV prevalence still means that large numbers of people are infected with HIV. The picture in this region is dominated by China. Much of the current spread of HIV in China is through injecting drug use and paid sex. In China, UNAIDS estimated the number to be between 390,000 and 1.1 million, following a previous report that ranged from 430,000 to 1.5 million people. East Asia has an estimates 3.5 million people living with HIV, with prevalence low in the 15-49 age range. HIV/AIDS has remained somewhat stable with an approximated 3.5 million cases since 2005. Thailand is the only east Asian country with an over 1% HIV prevalence, which has declined from 1.7% in 2001 to 1.1% in 2015. No cases have been reported in the Democratic People's Republic of Korea.
In the early 1990s, HIV spread in rural China through commercial plasma donations due to the lack of adequate infection prevention and control. In Japan, just over half of HIV/AIDS cases are officially recorded as occurring amongst homosexual men, with the remainder occurring in heterosexual contact, injection drug use, and unknown means.
In East Asia, men who have sex with men account for 18% of new HIV/AIDS cases and are therefore a key affected group along with sex workers and their clients who makeup 29% of new cases. This is also a noteworthy aspect because men who have sex with men had a prevalence of at least 5% or higher in countries in Asia and Pacific.

### Americas
#### Caribbean

The Caribbean is the second-most affected region in the world. Among adults aged 15–44, AIDS has become the leading cause of death. However, there has been a significant decrease in the number of infections per year in the Caribbean. There is a visible decrease in a graph presented by UNAIDS showing the number of new HIV infections from years 2015–2020. There has also been a 50% decrease in the number of deaths due to AIDS since 2010. The region's adult prevalence rate in 2011 was 0.9%. As of 2021, the prevalence rate among adults ages 15–49 was 1.2% with 14 000 new HIV cases presenting in both adults and children which is a 28% decrease from 2010.
HIV transmission occurs largely through heterosexual intercourse. A greater number of people who get infected with HIV/AIDS are heterosexuals. with two-thirds of AIDS cases in this region attributed to this route. Sex between men is also a significant route of transmission, even though it is heavily stigmatized and illegal in many areas. HIV transmission through injecting drug use remains rare, except in Bermuda and Puerto Rico.
Within the Caribbean, the country with the highest prevalence of HIV/AIDS is the Bahamas with a rate of 3.2% of adults with the disease. However, when comparing rates from 2004 to 2013, the number of newly diagnosed cases of HIV decreased by 4% over those years. Increased education and treatment drugs will help to decrease incidence levels even more.
According to the UNAIDS Global AIDS Update 2022, there is a significant gap when it comes to children and adults alike receiving treatments which is playing a part in inhibiting the world from reaching its 2023 goal of 75% viral suppression among children. This could be in part due to the high cost for treatment and services rounding to an estimated US$725 per person per year.

#### Central and South America

The populations of Central and South America have approximately 1.6 million people currently infected with HIV and this number has remained relatively unvarying with having a prevalence of approximately .4%. In Latin America, those infected with the disease have received help in the form of Antiretroviral treatment, with 75% of people with HIV receiving the treatment.
In these regions of the American continent, only Guatemala and Honduras have national HIV prevalence of over 1%. In these countries, HIV-infected men outnumber HIV-infected women by roughly 3:1.
With HIV/AIDS incidence levels rising in Central America, education is the most important step in controlling the spread of this disease. In Central America, many people do not have access to treatment drugs. This results in 8–14% of people dying from AIDS in Honduras. To reduce the incidence levels of HIV/AIDS, education and drug access needs to improve.
In a study of immigrants traveling to Europe, all asymptomatic persons were tested for a variety of infectious diseases. The prevalence of HIV among the 383 immigrants from Latin America was low, with only one person testing positive for a HIV infection. This data was collected from a group of immigrants with the majority from Bolivia, Ecuador and Colombia.

#### United States

Since the epidemic began in the early 1980s, 1,216,917 people have been diagnosed with AIDS in the US. In 2016, 14% of the 1.1 million people over age 13 living with HIV were unaware of their infection. The most recent CDC HIV Surveillance Report estimates that 38,281 new cases of HIV were diagnosed in the United States in 2017, a rate of 11.8 per 100,000 population. Men who have sex with men accounted for approximately 8 out of 10 HIV diagnoses among males. Regionally, the population rates (per 100,000 people) of persons diagnosed with HIV infection in 2015 were highest in the South (16.8), followed by the Northeast (11.6), the West (9.8), and the Midwest (7.6). Since 2015, HIV infections have decreased 8%, with 30,635 new cases reported in 2020. The highest incidence rates have continued to be measured in the South, with approximately 13% of the population unaware of their HIV status.
The most frequent mode of transmission of HIV continues to be through male homosexual sexual relations. In general, recent studies have shown that 1 in 6 gay and bisexual men were infected with HIV. As of 2014, in the United States, 83% of new HIV diagnoses among all males aged 13 and older and 67% of the total estimated new diagnoses were among homosexual and bisexual men. Those aged 13 to 24 also accounted for an estimated 92% of new HIV diagnoses among all men in their age group.
A review of studies containing data regarding the prevalence of HIV in transgender women found that nearly 11.8% self-reported that they were infected with HIV. Along with these findings, recent studies have also shown that transgender women are 34 times more likely to have HIV than other women. A 2008 review of HIV studies among transgender women found that 28 percent tested positive for HIV. In the National Transgender Discrimination Survey, 20.23% of black respondents reported being HIV-positive, with an additional 10% reporting that they were unaware of their status.
AIDS is one of the top three causes of death for African American men aged 25–54 and for African American women aged 35–44 years in the United States of America. In the United States, African Americans make up about 48% of the total HIV-positive population and make up more than half of new HIV cases, despite making up only 12% of the population. The main route of transmission for women is through unprotected heterosexual sex. African American women are 19 times more likely to contract HIV than other women.
By 2008, there was increased awareness that young African-American women in particular were at high risk for HIV infection. In 2010, African Americans made up 10% of the population but about half of the HIV/AIDS cases nationwide. This disparity is attributed in part to a lack of information about AIDS and a perception that they are not vulnerable, as well as to limited access to health-care resources and a higher likelihood of sexual contact with at-risk male sexual partners.
Since 1985, the incidence of HIV infection among women had been steadily increasing. In 2005 it was estimated that at least 27% of new HIV infections were in women. There has been increasing concern for the concurrency of violence surrounding women infected with HIV. In 2012, a meta-analysis showed that the rates of psychological trauma, including Intimate Partner Violence and PTSD in HIV positive women were more than five times and twice the national averages, respectively. In 2013, the White House commissioned an Interagency Federal Working Group to address the intersection of violence and women infected with HIV.
1996 would mark the first year since the beginning of the epidemic that the number of new HIV/AIDS cases would decline. A significant 47% decline compared to the previous year would also be reported in 1997.
There are also geographic disparities in AIDS prevalence in the United States, where it is most common in the large cities of California, esp. Los Angeles and San Francisco and the East Coast, ex. New York City and in urban cities of the Deep South. Rates are lower in Utah, Texas, and Northern Florida. Washington, D.C., the nation's capital, has the nation's highest rate of infection, at 3%. This rate is comparable to what is seen in west Africa, and is considered a severe epidemic.

#### Canada

In 2016, there were approximately 63,100 people living with HIV/AIDS in Canada. It was estimated that 9090 persons were living with undiagnosed HIV at the end of 2016. Mortality has decreased due to medical advances against HIV/AIDS, especially highly active antiretroviral therapy (HAART). HIV/AIDS prevalence is increasing most rapidly amongst Indigenous Canadians, with 11.3% of new infections in 2016. Canada aims to reach goals of the 90-90-90 strategy set by Join United Nations Programme on HIV/AIDS (UNAIDS) where 90% of those positive and living with HIV know their status, 90% of the diagnosed able to receive antiretroviral treatment, and 90% on treatment able to achieve viral suppression to eliminate the epidemic of AIDS by 2030.

### Eastern Europe and Central Asia

There is growing concern about a rapidly growing epidemic in Eastern Europe and Central Asia, where an estimated 1.23–3.7 million people were infected as of December 2011, though the adult (15–49) prevalence rate is low (1.1%). The rate of HIV infections began to grow rapidly from the mid-1990s, due to social and economic collapse, increased levels of intravenous drug use and increased numbers of sex workers. By 2010 the number of reported cases in Russia was over 450,000 according to the World Health Organization, up from 15,000 in 1995 and 190,000 in 2002. In June 2021, there are over 1.1 million people in Russia living with HIV.
Ukraine and Estonia also have growing numbers of infected people, with estimates of 240,000 and 7,400 respectively in 2018. Also, transmission of HIV is increasing through sexual contact and drug use among the young (<30 years). In this region there were between 130,000 and 180,000 new HIV infections reported in 2021.

### Western Europe

In most countries of Western Europe, AIDS cases have fallen to levels not seen since the original outbreak; many attribute this trend to aggressive educational campaigns, screening of blood transfusions and increased use of condoms. Also, the death rate from AIDS in Western Europe has fallen sharply, as new AIDS therapies have proven to be an effective (though expensive) means of suppressing HIV.
In this area, the routes of transmission of HIV is diverse, including paid sex, injecting drug use, mother to child, male with male sex and heterosexual sex. However, many new infections in this region occur through contact with HIV-infected individuals from other regions. The adult (15–49) prevalence in this region is 0.3% with between 570,000 and 890,000 people currently infected with HIV. Due to the availability of antiretroviral therapy, AIDS deaths have stayed low since the lows of the late 1990s. However, in some countries, a large share of HIV infections remain undiagnosed and there is worrying evidence of antiretroviral drug resistance among some newly HIV-infected individuals in this region.

### Oceania

There is a very large range of national situations regarding AIDS and HIV in this region. This is due in part to the large distances between the islands of Oceania. The wide range of development in the region also plays an important role. The prevalence is estimated at between 0.2% and 0.7%, with between 45,000 and 120,000 adults and children currently infected with HIV.
Papua New Guinea has one of the most serious AIDS epidemics in the region. According to UNAIDS, HIV cases in the country have been increasing at a rate of 30 percent annually since 1997, and the country's HIV prevalence rate in late 2006 was 1.3%.

## AIDS research and society

In June 2001, the United Nations held a Special General Assembly to intensify international action to fight the HIV/AIDS pandemic as a global health issue, and to mobilize the resources needed towards this aim, labelling the situation a "global crisis".
Regarding the social effects of the HIV/AIDS pandemic, some sociologists suggest that AIDS has caused a "profound re-medicalisation of sexuality".
There has been extensive research done with HIV since 2001 in the United States, The National Institutes of Health (NIH) which is an agency funded by the U.S. department of Health and Human Services (HHS) has substantially improved the health, treatment, and lives of many individuals across the nation. The human immunodeficiency virus (HIV) is generally the precursor to AIDS. To this day, there is no cure for the virus; However, various treatments and education programs have been made available over time.
NIH, is coordinated by the Office of AIDS Research (OAR) and this research carried out by nearly all the NIH Institutes and Centers, in both at NIH and at NIH-funded institutions worldwide. The NIH HIV/AIDS Research Program, represents the world's largest public investment in AIDS research. Other agencies like the National Institute of Allergy and Infectious Diseases have also made substantial efforts to provide the latest and newest research and treatment available.
The NIH found that in certain areas of the world, the correlation in risky behaviors and the acquisition of HIV/AIDS is causational. Consistent drug usage and related risk behaviors, such as the exchange of sex for drugs or money, are linked to an increased risk of HIV acquisition in marginalized areas. NIAID and other NIH institutes work to develop and optimize harm reduction interventions that decrease the risk of drug use-associated and sexual transmission of HIV among injecting and non-injecting drug users. Most organizations work collectively around the globe to understand, diagnose, treat, and battle the spread of this notorious disease, through the use of intervention and preventive programs the risk of acquiring HIV and the development of AIDS has dramatically dropped by 40% since its peak of cases back in 1998.
Despite the advancements in scientific research and treatment, to this day there's no available cure for HIV/AIDS. Yet major efforts to contain the disease and improve the lives of many individuals through modernized anti-viral therapy have resulted in positive and promising results that may one day lead to a cure. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) is one of the largest U.S. Government's response to the global HIV/AIDS epidemic and represents the largest commitment by any nation to address a single disease in history. PEPFAR provided HIV testing services for 79.6 million people in Fiscal Year 2019 and, as of September 30, 2019, supported lifesaving anti-retroviral therapy for nearly 15.7 million men, women, and children. As of the end of 2019, 25.4 million people with HIV (67%) were accessing antiretroviral therapy (ART) globally.
HIV treatment access is key to the global effort to end AIDS as a public health threat. Because HIV is more prevalent in urban areas of the United States, individuals living in rural areas generally don't participate or receive HIV diagnosis. The CDC found huge disparities in HIV cases between Northern and Southern regions of the Nation. At a rate of 15.9 the Southern regions account for a large number of reports of HIV; subsequently, regions like the North and Midwest account for general rates between 9 and 7.2 making it significantly lower in case prevalence. The development of an HIV vaccine has made little progress in the last forty years, but thanks to the development of mRNA technology used to quickly create COVID-19 vaccines for the SARS-CoV2 virus, creation of an HIV vaccine seems much more promising. The greatest challenge in applying the strategies of the COVID-19 vaccine is that HIV has a much greater number of variants that its vaccine needs to address.
According to the CDC, populations affected and with most reported cases of HIV are generally found in gay, bisexual, and other men who reported male-to-male sexual contact. In 2018, gay and bisexual men accounted for 69% of the 37,968 new HIV diagnoses and 86% of diagnoses among males. HIV doesn't only affect individuals in this category, heterosexuals tend to be affected by HIV as well. In 2018, heterosexuals accounted for 24% of the 37,968 new HIV diagnoses in the United States.
* Heterosexual men accounted for 8% of new HIV diagnoses.
* Heterosexual women accounted for 16% of new HIV diagnoses.
UNAIDS also suggested that the individuals who may also be at risk of acquiring this disease are generally:
* 28 times higher among men who have sex with men.
* 29 times higher among people who inject drugs.
* 30 times higher for sex workers.
* 13 times higher for transgender people.